Leading tRNA researcher joins Tevard’s efforts to transform tRNAs into novel treatments for serious genetic diseases CAMBRIDGE, Mass., August 3, 2022 Tevard Biosciences, the pioneer of tRNA-based therapies for severe genetic diseases, today announced the appointment of leading tRNA scientist Zoya Ignatova, Ph.D, to its scientific advisory board. “Dr. Ignatova’s work has profoundly impacted our […]
Leer Más
The Termeer Foundation, a nonprofit organization focused on connecting life science innovators and catalyzing the creation of new medicines, has named Tevard CEO and co-founder Daniel Fischer as a member of the Class of 2022 Henri Termeer Fellows. The Henri Termeer Fellowship honors “emerging leaders within the life science industry who have shown initial promise […]
Leer Más
New platform provides additional avenue for treating severe genetic diseases, joins Tevard’s tRNA-based platforms in broadly applicable suite of technologies Tevard Biosciences, the pioneer of tRNA-based treatments for severe genetic diseases, today announced an agreement to exclusively license “mRNA Amplifier” technology from the Johns Hopkins University. The technology will help form the basis of […]
Leer Más
Researchers’ deep expertise in tRNAs and gene translation bolsters Tevard’s efforts to address a broad range of genetic diseases CAMBRIDGE, Mass., March 9, 2022 Tevard Biosciences, the pioneer of tRNA-based treatments for severe genetic diseases, today announced the appointment of Paul Schimmel, Ph.D., Susan Ackerman, Ph.D., and Nicholas Ingolia, Ph.D., to its scientific advisory board. […]
Leer Más
Source: Nature Biotechnology Companies advance tRNA therapeutics to overcome mutant stoppages in protein synthesis shared by thousands of genetic diseases and cancers. Alltrna launched in November 2021 billing itself as “the world’s first tRNA platform company.” By engineering transfer RNA molecules — the cellular couriers of protein synthesis — the startup, backed by $50 million […]
Leer Más
Source: Chemical & Engineering News A new class of therapies based on transfer RNA could treat forms of cystic fibrosis, muscular dystrophy, genetic epilepsies, and more When Daniel Fischer cofounded Tevard Biosciences in 2017, he wasn’t trying to bet on the next hot RNA technology. His interest was more personal. His daughter Natasha has Dravet […]
Leer Más
CAMBRIDGE, Mass., May 19, 2021 /PRNewswire/ — Tevard Biosciences, a privately-held biotechnology company pioneering tRNA-based gene therapies for rare and severe genetic diseases, today announced the appointment of Gopi Shanker, Ph.D., as Chief Scientific Officer and as a member of the company’s executive leadership team. With more than 20 years of experience in industry and […]
Leer Más
CAMBRIDGE, Mass. and EMERYVILLE, Calif., Dec. 3, 2020 /PRNewswire/ — Tevard Biosciences, a privately-held biotechnology company pioneering tRNA-based gene therapies, and Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that the companies have entered into a collaboration to identify and develop novel tRNA-based gene therapies for Dravet syndrome and other genetic epilepsies. Read More
Leer Más
Photo Caption: Shared laboratory space at LabCentral in Kendall Square Cambridge, Massachusetts Boston-based startups Tevard Biosciences and QurAlis announced as winners of the Pfizer Neuroscience Golden Ticket Program In June 2018, Pfizer Kendall Square opened a call for interested U.S. startup companies focused on neuroscience to submit non-confidential proposals for a Pfizer-sponsored LabCentral “Golden […]
Leer Más